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conventional open lobectomy for patients with non-small-cell
lung cancer (NSCLC), to stratify potential differences in long-term
survival outcomes.
Methods: We established a multi-institutional registry for 4138
patients with NSCLC who underwent lobectomy between January,
2000, and December, 2007, from eight institutions in China. Age,
gender, histological type, and tumour staging, based on the latest
TNM classification, were entered into a non-parsimonious multi-
variable logistic-regression model. The predicted probability
derived from the logistic equation was used as the propensity
score for each individual. Based on similar propensity scores,
we matched 1356 of the 1584 patients who underwent VATS
lobectomy with 1356 of the 2554 patients who underwent open
lobectomy, and compared their long-term survival outcomes.
Findings: The mean age of the 2712 matched patients was 59
years (SD 11). After propensity matching, VATS and open lobec-
tomy were similar with regard to important prognostic variables.
In multivariate analysis, four prognostic factors were indepen-
dently associated with improved survival: gender (p = 0.001), his-
tological type (p < 0.001), pathological staging (p < 0.001), and
surgery type (lobectomy/sleeve resection vs. pneumonectomy
(p = 0.044). Patients who underwent VATS versus open lobectomy
had similar long-term survival (p = 0.101).
Interpretation: The current propensity-score analysis suggests
that well-matched patients with NSCLC who underwent VATS
lobectomy did not have inferior long-term survival outcomes
compared with those who underwent open lobectomy.
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Background: We investigated the significance of CD24 and CD44
expression for predicting response to chemotherapy, and progno-
sis, in patients with primary breast cancer.
Methods: Diagnosis of breast cancer was confirmed by core-
needle biopsy, and immunohistochemical studies were
performed. Preoperatively, patients received anthracycline-con-
taining chemotherapy. Expression of CD44 and CD24 was
assessed immunohistochemically and the association with che-
motherapy response and prognosis was analysed.
Findings: 139 women were enrolled in this study between 2001
and 2004. In correlation analysis, CD24 expression was negatively
associated with pathological response to chemotherapy
(p = 0.0003). A machine learning technique with an alternating
decision tree showed that four logical rules are involved in pre-
dicting response, depending on the combination of CD24, HER2,
tumour stage, CD44, progesterone receptor, and patient age. In
survival analysis, patients who were CD44 (++) showed a signifi-
cantly favourable prognosis compared with others (p = 0.0002).
Multivariate analysis showed that CD44 expression had an inde-
pendent prognostic value (p < 0.001).
Interpretation: We found a significant correlation between CD44
expression and prognosis, and between CD24 expression and
response to chemotherapy. CD24 and CD44 expression could be
useful predictive markers, although further studies are needed.
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Introduction: The American Cancer Society estimated 70,980
new cases of bladder cancer in the USA during 2009, with
approximately 14,330 bladder-cancer-related deaths during the
same period. Cystoscopy, the gold standard diagnostic evaluation
for detection of bladder cancer and surveillance after therapy, is
invasive, expensive, and unpopular among patients. Urine
cytology, as an adjunct to cystoscopy, is less sensitive for low-
grade tumours. This study evaluated the clinical significance of
survivin (an inhibitor of apoptosis) mRNA expression in diagnosis
of transitional-cell carcinoma (TCC) in patients with bladder
cancer.
Methods: Quantitative detection of survivin mRNA expression
was evaluated in exfoliated cells in urine, by use of real-time
quantitative (qRT)-PCR, in 135 patients with suspicion of new or
recurrent bladder cancer, prior to transurethral resection. Of 135
cases, 98 were histologically proven TCC, whereas 37 had other,
benign urological diseases. Fifteen healthy volunteers were also
included, as well as 62 patients with treated superficial bladder
cancer who had a current negative biopsy and were receiving fol-
low-up care.
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